微小残留疾病检测市场－全球产业规模、份额、趋势、机会和预测，依技术、应用、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球微小残留病灶（MRD）检测市场规模为14.5亿美元，预计到2030年将以8.70%的复合年增长率增长至23.9亿美元。微小残留病灶（MRD）检测能够识别患者治疗后体内残留的微量癌细胞，这些癌细胞通常无法透过传统方法检测到，但却能显着预测疾病復发。推动这一全球市场扩张的主要因素是各种血液系统恶性肿瘤发病率的上升以及诊断技术的不断进步，例如新一代定序和高灵敏度流式细胞仪。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球微小残留疾病（MRD）检测市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术分类（流式细胞仪、聚合酶炼式反应、次世代定序、其他）
  • 依申请类别（白血病、淋巴瘤、多发性骨髓瘤、其他）
  • 按最终使用者（医院和专科诊所、学术和研究机构、临床实验室、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美微小残留疾病（MRD）检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲微小残留疾病（MRD）检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区微小残留疾病（MRD）检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲微小残留疾病（MRD）检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲微小残留疾病（MRD）检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球微小残留疾病（MRD）检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• ICON plc
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Laboratory Corporation of America Holdings
• Natera, Inc.
• Cergentis BV
• OPKO Health, Inc.
• Sysmex Corporation
• Mission Bio, Inc.
• Invivoscribe, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Minimal Residual Disease (MRD) Testing Market, valued at USD 1.45 Billion in 2024, is projected to experience a CAGR of 8.70% to reach USD 2.39 Billion by 2030. Minimal residual disease (MRD) testing identifies minute quantities of cancer cells remaining in a patient's body post-treatment, often undetectable by conventional methods, which significantly predict disease relapse. This global market's expansion is fundamentally driven by the rising incidence of various hematological malignancies and continuous advancements in diagnostic technologies, such as next-generation sequencing and highly sensitive flow cytometry.

Key Market Drivers

The escalating global incidence of cancer and hematological malignancies represents a primary force propelling the minimal residual disease testing market. As the population grows and ages, the number of new cancer diagnoses continues to rise, directly increasing the patient pool requiring sophisticated monitoring tools throughout their treatment journey and follow-up. MRD testing becomes crucial in managing these conditions by offering precise detection of residual disease after therapy, guiding subsequent treatment decisions, and identifying patients at high risk of relapse.

Key Market Challenges

The high cost associated with advanced minimal residual disease testing technologies represents a significant impediment to market expansion. These economic considerations directly limit patient access and hinder widespread adoption, especially in healthcare systems facing budget constraints or where high patient out-of-pocket expenses are prevalent. The advanced methodologies and specialized infrastructure required for these tests contribute to their elevated cost, thereby making them less attainable for a wider patient demographic.

Key Market Trends

The expanding clinical utility of minimal residual disease (MRD) testing in solid tumors represents a significant market trend, moving beyond its established role in hematological malignancies. This shift is driven by the clear need for more precise post-treatment monitoring and recurrence prediction in a broader patient population. According to the American Cancer Society, in 2023, an estimated 1,958,310 new cancer cases were projected to occur in the United States, with solid tumors constituting the vast majority of these diagnoses, highlighting a substantial and underserved patient base for advanced monitoring solutions. This expansion is further underscored by industry developments, such as Illumina Inc. 's announcement in January 2024 of a collaboration with Janssen Research & Development, LLC to develop a novel molecular residual disease assay. This whole-genome sequencing multi-cancer research solution is specifically designed to detect circulating tumor DNA for various solid tumor indications, signaling growing investment and technological application in this area.

Key Market Players

• ICON plc
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Laboratory Corporation of America Holdings
• Natera, Inc.
• Cergentis B.V.
• OPKO Health, Inc.
• Sysmex Corporation
• Mission Bio, Inc.
• Invivoscribe, Inc.

Report Scope:

In this report, the Global Minimal Residual Disease (MRD) Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Minimal Residual Disease (MRD) Testing Market, By Technology:

• Flow Cytometry
• Polymerase Chain Reaction
• Next Generation Sequencing
• Others

Minimal Residual Disease (MRD) Testing Market, By Application:

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

Minimal Residual Disease (MRD) Testing Market, By End User:

• Hospitals & Specialty Clinics
• Academic & Research Institutions
• Clinical Laboratories
• Others

Minimal Residual Disease (MRD) Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Minimal Residual Disease (MRD) Testing Market.

Available Customizations:

Global Minimal Residual Disease (MRD) Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Minimal Residual Disease (MRD) Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, Others)
  • 5.2.2. By Application (Leukemia, Lymphoma, Multiple Myeloma, Others)
  • 5.2.3. By End User (Hospitals & Specialty Clinics, Academic & Research Institutions, Clinical Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Minimal Residual Disease (MRD) Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Minimal Residual Disease (MRD) Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Minimal Residual Disease (MRD) Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Minimal Residual Disease (MRD) Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Minimal Residual Disease (MRD) Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Minimal Residual Disease (MRD) Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Minimal Residual Disease (MRD) Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Minimal Residual Disease (MRD) Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Minimal Residual Disease (MRD) Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Minimal Residual Disease (MRD) Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Minimal Residual Disease (MRD) Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Minimal Residual Disease (MRD) Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Minimal Residual Disease (MRD) Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Minimal Residual Disease (MRD) Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Minimal Residual Disease (MRD) Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Minimal Residual Disease (MRD) Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Minimal Residual Disease (MRD) Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Minimal Residual Disease (MRD) Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Minimal Residual Disease (MRD) Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Minimal Residual Disease (MRD) Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Minimal Residual Disease (MRD) Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Minimal Residual Disease (MRD) Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Minimal Residual Disease (MRD) Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Minimal Residual Disease (MRD) Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Minimal Residual Disease (MRD) Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ICON plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche AG
• 15.3. Bio-Rad Laboratories, Inc.
• 15.4. Laboratory Corporation of America Holdings
• 15.5. Natera, Inc.
• 15.6. Cergentis B.V.
• 15.7. OPKO Health, Inc.
• 15.8. Sysmex Corporation
• 15.9. Mission Bio, Inc.
• 15.10. Invivoscribe, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer